Aaron L. Moye

Aaron joined DoriNano as Chief Operating Officer in 2025, bringing his experience and passion for turning breakthrough science into real-world therapies. Prior to DoriNano, he served as Chief Executive Officer, Co-Founder, and Board Member of Cellforma, Inc., a Cambridge-based biotechnology company developing CFA-001, a first-in-class allogeneic regenerative cell therapy for the treatment of fibrotic lung diseases.

An accomplished scientist and life science entrepreneur, Aaron has published extensively in the fields of oncology and cell therapy in high-impact journals and has been recognized with numerous awards for his contributions to translational research, company building, and therapeutic development. He also gives lectures at the graduate level and advises students and scientists on the topics of life science entrepreneurship and innovation.

Aaron received a Bachelor of Medical Science (Honors) and PhD from the University of Sydney. He completed his postdoctoral training at Harvard Medical School and Boston Children’s Hospital as a Damon Runyon Cancer Research Foundation and Burroughs Wellcome Fund Fellow.